RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on May 20, 2021, specifically the Company's 2021 Annual Meeting of Stockholders. Relmada Therapeutics, Inc. is a Nevada corporation with its principal executive offices in New York, NY, and its common stock trades on The NASDAQ Stock Market LLC under the symbol RLMD.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity matters. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Corporate Actions
The following material actions were approved by stockholders at the Annual Meeting:
- Equity Incentive Plan Approval: Stockholders approved the 2021 Equity Incentive Plan, authorizing the issuance of 1,500,000 shares of common stock for employee incentives.
- Director Elections: Two Class III directors were elected for a 36-month term:
- John Glasspool: 9,072,604 votes For; 2,147,011 votes Withheld.
- Paul Kelly: 10,472,018 votes For; 747,597 votes Withheld.
- Auditor Ratification: Stockholders ratified the appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ended December 31, 2020.
- Executive Compensation: Stockholders approved the advisory vote on executive compensation and determined that future advisory votes on this matter will occur every three years.
Outlook, Risks, and Management Commentary
The filing contains no management commentary regarding future business outlook, specific risks, contingencies, or unusual items. The document focuses strictly on the results of the shareholder vote and the adoption of the 2021 Equity Incentive Plan.
Investor Verification Checklist
- Verify the terms of the 2021 Equity Incentive Plan (Exhibit 10.1) to understand vesting schedules and eligibility.
- Review the 2021 Proxy Statement (filed March 31, 2021) for detailed background on the director nominees and executive compensation rationale.
- Confirm the continued service of Class I and Class II directors (Eric Schmidt, Charles J. Casamento, and Sergio Traversa) as noted in the filing.
- Check subsequent filings for the actual issuance of shares under the newly approved 1.5 million share plan.